Skip to main content
NASDAQ:NLSP

NLS Pharmaceutics Competitors

$3.43
+0.23 (+7.19 %)
(As of 05/14/2021 12:25 PM ET)
Add
Compare
Today's Range
$3.31
$3.43
50-Day Range
$2.91
$4.12
52-Week Range
$2.06
$7.35
Volume1,098 shs
Average Volume2.85 million shs
Market Capitalization$40.40 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

NLS Pharmaceutics (NASDAQ:NLSP) Vs. LBPH, IPA, GANX, EVAX, LGVN, and VRDN

Should you be buying NLSP stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to NLS Pharmaceutics, including Longboard Pharmaceuticals (LBPH), ImmunoPrecise Antibodies (IPA), Gain Therapeutics (GANX), Evaxion Biotech A/S (EVAX), Longeveron (LGVN), and Viridian Therapeutics (VRDN).

NLS Pharmaceutics (NASDAQ:NLSP) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Valuation and Earnings

This table compares NLS Pharmaceutics and Longboard Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NLS PharmaceuticsN/AN/AN/AN/AN/A
Longboard PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for NLS Pharmaceutics and Longboard Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NLS Pharmaceutics00303.00
Longboard Pharmaceuticals00503.00

NLS Pharmaceutics currently has a consensus target price of $10.6667, indicating a potential upside of 210.98%. Longboard Pharmaceuticals has a consensus target price of $32.75, indicating a potential upside of 281.70%. Given Longboard Pharmaceuticals' higher possible upside, analysts plainly believe Longboard Pharmaceuticals is more favorable than NLS Pharmaceutics.

Profitability

This table compares NLS Pharmaceutics and Longboard Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NLS PharmaceuticsN/AN/AN/A
Longboard PharmaceuticalsN/AN/AN/A

Summary

Longboard Pharmaceuticals beats NLS Pharmaceutics on 2 of the 2 factors compared between the two stocks.

ImmunoPrecise Antibodies (NASDAQ:IPA) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Valuation & Earnings

This table compares ImmunoPrecise Antibodies and NLS Pharmaceutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoPrecise AntibodiesN/AN/AN/AN/AN/A
NLS PharmaceuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for ImmunoPrecise Antibodies and NLS Pharmaceutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoPrecise Antibodies01002.00
NLS Pharmaceutics00303.00

NLS Pharmaceutics has a consensus price target of $10.6667, indicating a potential upside of 210.98%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, analysts plainly believe NLS Pharmaceutics is more favorable than ImmunoPrecise Antibodies.

Profitability

This table compares ImmunoPrecise Antibodies and NLS Pharmaceutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoPrecise AntibodiesN/AN/AN/A
NLS PharmaceuticsN/AN/AN/A

Summary

NLS Pharmaceutics beats ImmunoPrecise Antibodies on 3 of the 3 factors compared between the two stocks.

Gain Therapeutics (NASDAQ:GANX) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Profitability

This table compares Gain Therapeutics and NLS Pharmaceutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gain TherapeuticsN/AN/AN/A
NLS PharmaceuticsN/AN/AN/A

Valuation and Earnings

This table compares Gain Therapeutics and NLS Pharmaceutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain TherapeuticsN/AN/AN/AN/AN/A
NLS PharmaceuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for Gain Therapeutics and NLS Pharmaceutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gain Therapeutics00203.00
NLS Pharmaceutics00303.00

Gain Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 220.17%. NLS Pharmaceutics has a consensus price target of $10.6667, indicating a potential upside of 210.98%. Given Gain Therapeutics' higher possible upside, research analysts clearly believe Gain Therapeutics is more favorable than NLS Pharmaceutics.

Evaxion Biotech A/S (NASDAQ:EVAX) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Profitability

This table compares Evaxion Biotech A/S and NLS Pharmaceutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evaxion Biotech A/SN/AN/AN/A
NLS PharmaceuticsN/AN/AN/A

Valuation and Earnings

This table compares Evaxion Biotech A/S and NLS Pharmaceutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion Biotech A/SN/AN/AN/AN/AN/A
NLS PharmaceuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for Evaxion Biotech A/S and NLS Pharmaceutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evaxion Biotech A/S00203.00
NLS Pharmaceutics00303.00

Evaxion Biotech A/S presently has a consensus price target of $18.00, indicating a potential upside of 239.62%. NLS Pharmaceutics has a consensus price target of $10.6667, indicating a potential upside of 210.98%. Given Evaxion Biotech A/S's higher possible upside, research analysts clearly believe Evaxion Biotech A/S is more favorable than NLS Pharmaceutics.

Longeveron (NASDAQ:LGVN) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Profitability

This table compares Longeveron and NLS Pharmaceutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LongeveronN/AN/AN/A
NLS PharmaceuticsN/AN/AN/A

Valuation and Earnings

This table compares Longeveron and NLS Pharmaceutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LongeveronN/AN/AN/AN/AN/A
NLS PharmaceuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for Longeveron and NLS Pharmaceutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longeveron0000N/A
NLS Pharmaceutics00303.00

NLS Pharmaceutics has a consensus price target of $10.6667, indicating a potential upside of 210.98%. Given NLS Pharmaceutics' higher possible upside, analysts clearly believe NLS Pharmaceutics is more favorable than Longeveron.

Summary

NLS Pharmaceutics beats Longeveron on 2 of the 2 factors compared between the two stocks.

Viridian Therapeutics (NASDAQ:VRDN) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares Viridian Therapeutics and NLS Pharmaceutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Viridian TherapeuticsN/AN/AN/A
NLS PharmaceuticsN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Viridian Therapeutics and NLS Pharmaceutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Viridian Therapeutics00203.00
NLS Pharmaceutics00303.00

Viridian Therapeutics presently has a consensus price target of $34.00, indicating a potential upside of 94.06%. NLS Pharmaceutics has a consensus price target of $10.6667, indicating a potential upside of 210.98%. Given NLS Pharmaceutics' higher probable upside, analysts plainly believe NLS Pharmaceutics is more favorable than Viridian Therapeutics.

Earnings & Valuation

This table compares Viridian Therapeutics and NLS Pharmaceutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian TherapeuticsN/AN/AN/AN/AN/A
NLS PharmaceuticsN/AN/AN/AN/AN/A

Summary

NLS Pharmaceutics beats Viridian Therapeutics on 2 of the 2 factors compared between the two stocks.


NLS Pharmaceutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
LBPH
Longboard Pharmaceuticals
1.9$8.58+2.1%$148.19 millionN/A0.00
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$7.85+4.5%$143.77 millionN/A0.00Gap Up
GANX
Gain Therapeutics
1.7$9.37+3.9%$106.89 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$5.30+5.7%$101.76 millionN/A0.00News Coverage
Gap Up
Trading Halted
LGVN
Longeveron
0.0$5.20+1.9%$98.58 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$17.52+3.8%$68.47 millionN/A0.00News Coverage
Gap Up
UPC
Universe Pharmaceuticals
0.0$3.20+3.4%$67.21 millionN/A0.00Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
1.0$4.60+6.5%$49.29 millionN/A0.00Gap Down
CUBT
Curative Biotechnology
0.0$0.11+8.7%$44.64 millionN/A0.00Gap Up
Viracta Therapeutics logo
VIRX
Viracta Therapeutics
1.5$7.66+0.0%$39.63 millionN/A0.00Analyst Downgrade
Gap Up
VIRI
Virios Therapeutics
1.3$4.71+2.1%$39.23 millionN/A0.00News Coverage
CMMB
Chemomab Therapeutics
1.7$17.80+6.8%$38.77 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Up
VYNT
Vyant Bio
0.0$3.27+11.9%$31.70 millionN/A0.00Upcoming Earnings
News Coverage
MYMD
MyMD Pharmaceuticals
0.0$3.63+0.3%$30.31 millionN/A0.00Upcoming Earnings
VLON
Vallon Pharmaceuticals
0.0$3.71+1.1%$25.27 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$3.85+2.6%$19.04 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$3.18+3.1%$17.91 millionN/A0.00Gap Up
PALI
Palisade Bio
0.0$3.94+16.8%$13.26 millionN/A0.00Upcoming Earnings
Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.32+0.4%$0.00N/A0.00Earnings Announcement
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.06+0.0%$0.00N/A0.00Gap Down
SCPS
Scopus BioPharma
1.4$5.53+6.5%$0.00N/A0.00
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.